Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
AGIO Financials Agios Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $54M | -$413M | 88.3% | -873.9% | -$377M | — | $89M |
| 2024 | $36M | $674M | 88.6% | -1166.5% | -$392M | — | $76M |
| 2023 | $27M | -$352M | 89.3% | -1459.5% | -$297M | — | $88M |
| 2022 | $14M | -$232M | 88.0% | -2732.1% | -$314M | — | $139M |
| 2021 | $0 | $1.6B | — | — | -$413M | — | $203M |
| 2020 | $0 | -$327M | — | — | -$305M | — | $127M |
| 2019 | $118M | -$411M | 98.9% | -268.2% | -$383M | — | $81M |
| 2018 | $94M | -$346M | 98.5% | -384.0% | -$311M | — | $71M |
| 2017 | $43M | -$315M | 100.0% | -745.8% | -$290M | — | $103M |
| 2016 | $70M | -$198M | 100.0% | -287.6% | $29M | — | $161M |
| 2015 | — | -$118M | — | — | -$97M | — | $72M |
| 2014 | — | -$54M | — | — | — | — | $14M |
| 2013 | — | -$39M | — | — | -$58M | — | $72M |
| 2012 | — | -$20M | — | — | -$51M | — | $91M |
| 2011 | — | -$24M | — | — | -$17M | — | $118M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $21M | -$99M | 93.6% | -530.3% | -$120M | — | $114M |
| Dec '25 | $20M | -$108M | 90.6% | -608.9% | -$97M | — | $89M |
| Sep '25 | $13M | -$103M | 87.0% | -907.4% | -$90M | — | $93M |
| Jun '25 | $12M | -$112M | 86.3% | -1020.1% | -$78M | — | $81M |
| Mar '25 | $9M | -$89M | 87.6% | -1222.0% | -$112M | — | $79M |
| Dec '24 | $11M | -$97M | 88.3% | -1165.3% | -$134M | — | $76M |
| Sep '24 | $9M | $948M | 91.3% | -1146.9% | -$85M | — | $254M |
| Jun '24 | $9M | -$96M | 82.6% | -1228.3% | -$73M | — | $85M |
| Mar '24 | $8M | -$82M | 92.3% | -1124.3% | -$100M | — | $119M |
| Dec '23 | $7M | -$96M | 91.7% | -1496.2% | -$73M | — | $88M |
| Sep '23 | $7M | -$91M | 91.4% | -1363.7% | -$62M | — | $64M |
| Jun '23 | $7M | -$84M | 83.5% | -1396.0% | -$67M | — | $85M |
| Mar '23 | $6M | -$81M | 90.1% | -1615.5% | -$96M | — | $104M |
| Dec '22 | $4M | $37M | 90.4% | -2301.0% | -$66M | — | $139M |
| Sep '22 | $4M | -$82M | 85.3% | -2590.7% | -$71M | — | $122M |
| Jun '22 | $6M | -$92M | 92.2% | -1749.2% | -$76M | — | $89M |
| Mar '22 | $832000 | -$95M | 59.3% | -12156.9% | -$101M | — | $80M |
| Dec '21 | $0 | -$95M | — | — | -$89M | — | $203M |
| Sep '21 | $0 | -$89M | — | — | -$85M | — | $400M |
| Jun '21 | $0 | -$86M | — | — | -$118M | — | $969M |
Valuation over time
How the market has priced AGIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 2.9× (Dec '24) to 2.6× (Nov '25).
- The price-to-sales ratio has fallen from 95.9× (Mar '23) to 39.8× (Jun '26).
P/E
P/S
Frequently asked questions
Is AGIO growing its revenue and profit?
See the revenue and net-income charts above for Agios Pharmaceuticals, Inc.'s multi-year trend.
How much debt does AGIO have?
As of FY2025, Agios Pharmaceuticals, Inc. reported — of total debt against $89M of cash.
What is AGIO's profit margin?
In FY2025, gross margin was 88.3%, operating margin -873.9%, and net margin -764.4%.
What is AGIO's P/E ratio?
As of Jun '26, Agios Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 2.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.